Group 1 - Kiniksa Pharmaceuticals International, plc (KNSA) closed at $30.26, with an 8.5% gain over the past four weeks, and a mean price target of $41.14 suggests a 36% upside potential [1] - The mean estimate includes seven short-term price targets with a standard deviation of $7.45, indicating variability among analysts; the lowest estimate is $32.00 (5.8% increase), while the highest is $54.00 (78.5% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with a 26.6% increase in the Zacks Consensus Estimate for the current year, indicating potential upside for KNSA [11][12] Group 2 - KNSA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for near-term upside [13] - The clustering of price targets with a low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] - While price targets should not be the sole basis for investment decisions, they can provide a useful starting point for further research into the stock's fundamental drivers [10][14]

Core Viewpoint - The sustainability of a stock trend is crucial for successful short-term investing, and various factors must be considered to maintain momentum in stock prices [1][2]. Group 1: Stock Performance - Kiniksa Pharmaceuticals International, plc (KNSA) has shown a solid price increase of 13.3% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - The stock has also increased by 8.5% in the last four weeks, suggesting that the upward trend is still intact [5]. - KNSA is currently trading at 88.2% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - KNSA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting strong optimism from the brokerage community regarding its near-term price performance [7]. - The Zacks Rank system has a proven track record, with Rank 1 stocks generating an average annual return of +25% since 1988 [7]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for identifying stocks like KNSA that have the fundamental strength to maintain their upward trend [3]. - There are additional stocks that meet the criteria of the "Recent Price Strength" screen, providing further investment opportunities [8]. - The effectiveness of stock-picking strategies can be backtested using the Zacks Research Wizard, which includes successful stock-picking strategies [9].

[PART I — FINANCIAL INFORMATION](index=7&type=section&id=PART%20I%20%E2%80%94%20FINANCIAL%20INFORMATION) [Financial Statements (unaudited)](index=7&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) Unaudited financials show total assets grew to **$661.2 million**, with H1 2025 net income of **$26.4 million** from ARCALYST revenue [Consolidated Balance Sheets](index=7&type=section&id=Consolidated%20Balance%20Sheets) Total assets increased to **$661.2 million** by June 30, 2025, with shareholders' equity at **$495.0 million**, driven by cash and inventory Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $192,037 | $183,581 | | Inventory | $48,181 | $26,364 | | Total current assets | $420,311 | $331,799 | | Total assets | $661,150 | $580,553 | | **Liabilities & Equity** | | | | Total current liabilities | $117,827 | $100,621 | | Total liabilities | $166,143 | $142,117 | | Total shareholders' equity | $495,007 | $438,436 | [Consolidated Statements of Operations and Comprehensive Income (Loss)](index=8&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20(Loss)) H1 2025 saw net income of **$26.4 million**, a turnaround from loss, with total revenue at **$294.6 million** from ARCALYST sales Statement of Operations Summary (in thousands) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $156,797 | $108,631 | $294,582 | $188,489 | | Income (Loss) from Operations | $20,160 | $(117) | $33,432 | $(16,659) | | Net Income (Loss) | $17,832 | $(3,908) | $26,371 | $(21,612) | | Diluted EPS | $0.23 | $(0.06) | $0.34 | $(0.31) | - The shift from a net loss to net income was primarily driven by a **52% YoY increase** in net product revenue for Q2 and a **61% YoY increase** for H1 2025[22](index=22&type=chunk) [Consolidated Statements of Cash Flows](index=10&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow improved to **$50.4 million** for H1 2025, increasing cash and cash equivalents by **$8.5 million** overall Cash Flow Summary (in thousands) | Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $50,414 | $9,155 | | Net cash used in investing activities | $(55,424) | $(21,273) | | Net cash provided by financing activities | $13,466 | $3,435 | | **Net increase (decrease) in cash** | **$8,456** | **$(8,683)** | [Notes to Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) Notes detail accounting policies, UK redomiciliation, ARCALYST growth, mavrilimumab termination, and manufacturing commitments - The company completed its redomiciliation from Bermuda to the United Kingdom in June 2024, becoming Kiniksa Pharmaceuticals International, plc[29](index=29&type=chunk) - As of June 30, 2025, the company had cash, cash equivalents, and short-term investments of **$307.8 million** and believes these funds are sufficient for at least the next twelve months of operations[35](index=35&type=chunk) - The company has total manufacturing purchase commitments of **$161.6 million**, with **$136.7 million** related to the ARCALYST technology transfer and supply agreement with Samsung[126](index=126&type=chunk)[202](index=202&type=chunk) - In April 2025, the company and Huadong mutually terminated their collaboration agreement for mavrilimumab[70](index=70&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=30&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes strong H1 2025 performance to ARCALYST success, with net product revenue up **61%** to **$294.6 million**, yielding **$26.4 million** net income - The company's primary commercial product is ARCALYST®, an IL-1α and IL-1β cytokine trap approved for recurrent pericarditis and other rare diseases. The pipeline is focused on cardiovascular indications, including KPL-387 for recurrent pericarditis[137](index=137&type=chunk)[138](index=138&type=chunk) - Development of abiprubart was discontinued in February 2025, and the company is exploring strategic alternatives for the asset. The license agreement for mavrilimumab was also terminated[140](index=140&type=chunk)[142](index=142&type=chunk) Financial Results Comparison (Six Months Ended June 30) | Metric (in millions) | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Product revenue, net | $294.6 | $182.3 | +$112.3 | | Total revenue | $294.6 | $188.5 | +$106.1 | | R&D Expenses | $38.1 | $50.4 | -$12.3 | | SG&A Expenses | $90.4 | $81.1 | +$9.3 | | Net Income (Loss) | $26.4 | $(21.6) | +$48.0 | - The company believes its cash, cash equivalents, and short-term investments of **$307.8 million** as of June 30, 2025, are sufficient to fund operations and capital expenditures for at least the next 12 months[145](index=145&type=chunk)[201](index=201&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=43&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Market risk exposure primarily relates to interest rate sensitivities on short-term investments, with no material changes reported - The company's primary market risk exposure is interest rate sensitivity on its short-term investments. No material changes were reported for the quarter[218](index=218&type=chunk) [Controls and Procedures](index=43&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of June 30, 2025, with no material changes to internal control over financial reporting - The principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures were effective as of June 30, 2025[220](index=220&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[221](index=221&type=chunk) [PART II — OTHER INFORMATION](index=44&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) [Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) The company is not a party to any material legal proceedings and has no litigation contingency reserves - The company is not currently a party to any material legal proceedings[224](index=224&type=chunk) [Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) Key risks include ARCALYST commercialization, pricing, clinical development, third-party manufacturing, and IP protection [Risks Related to Commercialization](index=44&type=section&id=Risks%20Related%20to%20Commercialization) ARCALYST commercial success faces risks in revenue growth, specialty pharmacy reliance, and favorable third-party payor reimbursement - Continued commercialization of ARCALYST is subject to risks including manufacturing sufficiency, prescriber adoption, and competition, which could impair revenue generation[227](index=227&type=chunk)[228](index=228&type=chunk) - Successful commercialization depends on third-party payors providing favorable coverage and reimbursement, which is subject to cost-control efforts and potential restrictions[234](index=234&type=chunk)[235](index=235&type=chunk) - The market opportunity for ARCALYST and other product candidates may be smaller than estimated, which could adversely affect revenue and profitability if the addressable patient population is lower than projected[249](index=249&type=chunk)[250](index=250&type=chunk) [Risks Related to Product Development](index=58&type=section&id=Risks%20Related%20to%20Product%20Development) Product development faces risks: lengthy, expensive clinical trials, uncertain outcomes, enrollment challenges, and potential undesirable side effects - Clinical drug development is a long, costly process with uncertain outcomes. The company may face substantial delays or fail to demonstrate the required safety and efficacy for its product candidates[288](index=288&type=chunk) - Enrolling a sufficient number of patients in clinical trials is challenging, particularly for rare diseases, and difficulties in enrollment could delay or prevent trial completion[303](index=303&type=chunk) - Undesirable side effects or safety risks from product candidates could delay or prevent regulatory approval, lead to a more restrictive label, or result in market withdrawal after approval[306](index=306&type=chunk) [Risks Related to Manufacturing and Our Reliance on Third Parties](index=68&type=section&id=Risks%20Related%20to%20Manufacturing%20and%20Our%20Reliance%20on%20Third%20Parties) Reliance on third-party CDMOs creates supply, cost, and quality risks, especially with the complex ARCALYST technology transfer to Samsung - The company relies on third-party CDMOs for manufacturing, which increases the risk of insufficient quantities, unacceptable costs or quality, and potential delays to development and commercialization[347](index=347&type=chunk) - A technology transfer of ARCALYST drug substance manufacturing from Regeneron to Samsung is underway and is subject to significant risks, including potential delays, comparability issues, and the need for FDA approval[367](index=367&type=chunk)[368](index=368&type=chunk)[369](index=369&type=chunk) - The company depends on single-source suppliers for critical components of ARCALYST and its pipeline candidates. The loss of any of these suppliers could significantly harm the business[375](index=375&type=chunk) [Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities](index=107&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities,%20Use%20of%20Proceeds%20and%20Issuer%20Purchases%20of%20Equity%20Securities) No unregistered sales of equity, use of proceeds, or issuer purchases of equity securities were reported - None reported[575](index=575&type=chunk) [Defaults Upon Senior Securities](index=107&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported - None reported[576](index=576&type=chunk) [Mine Safety Disclosures](index=107&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - None reported[577](index=577&type=chunk) [Other Information](index=107&type=section&id=Item%205.%20Other%20Information) The company disclosed the adoption of Rule 10b5-1 trading arrangements by two officers during Q2 2025 Adoption of Trading Arrangements by Officers | Name | Title | Action | Effective Date | Maximum Shares in Plan | | :--- | :--- | :--- | :--- | :--- | | Sanj K. Patel | CEO and Chairman | Adoption | May 7, 2025 | 355,590 | | Michael R. Megna | SVP, Finance and CAO | Adoption | May 24, 2025 | 36,145 | [Exhibits](index=108&type=section&id=Item%206.%20Exhibits) Exhibits filed with Form 10-Q include incentive plan documents, a consulting agreement, and officer certifications - The report includes exhibits such as the KPL-387 Long-Term Incentive Plan, related award agreements, a consulting agreement, and certifications by the CEO and CFO[580](index=580&type=chunk)

Over the last four quarters, the company has surpassed consensus EPS estimates two times. Kiniksa Pharmaceuticals International, plc, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $156.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.92%. This compares to year-ago revenues of $108.63 million. The company has topped consensus revenue estimates four times over the last four quarters. Kiniksa Pharmaceuticals International, plc ( ...

Financial Data and Key Metrics Changes - Kynixa reported net revenue of $156.8 million in Q2 2025, representing a growth of $19 million over Q1 2025 and a 52% year-over-year increase compared to Q2 2024 [6][11][17] - The company raised its full-year 2025 net sales guidance for Arclis to between $625 million and $640 million, up from the previous range of $590 million to $600 million [7][17] - Net income for Q2 2025 was $17.8 million, compared to a net loss of $3.9 million in the same quarter last year [19] Business Line Data and Key Metrics Changes - Arclis revenue grew 52% year-over-year in Q2 2025, driven by strong growth in new patient enrollments and prescribers [11][19] - The average duration of therapy for patients on Arclis was approximately 30 months, with patient compliance remaining strong at over 85% [13][55] Market Data and Key Metrics Changes - The penetration into the multiple recurrence population increased from approximately 13% at the end of 2024 to approximately 15% at the end of Q2 2025 [12][26] - Approximately 20% of total prescriptions for Arclis were from patients on their first recurrence, indicating a growing acceptance among healthcare professionals to prescribe early in the disease [14][28] Company Strategy and Development Direction - Kynixa is committed to maximizing the potential of Arclis and advancing its clinical portfolio, including the development of KPL-387, a liquid formulation IL-1 receptor antagonist [9][21] - The company aims to drive additional innovation for patients with recurrent pericarditis and maintain its leadership position in the market [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of Arclis, highlighting the strong commercial execution and the potential for future launches of novel therapies [18][21] - The company remains focused on creating value while maintaining a cash flow positive operating plan [19][57] Other Important Information - Kynixa's cash balance increased by approximately $40 million to $307.8 million in Q2 2025, supporting ongoing investments without needing to access capital markets [19] - The company has initiated a phase two-three clinical trial for KPL-387, with data expected in the second half of next year [9][10] Q&A Session Summary Question: Trends in first recurrence setting for Arclis - Management noted a significant opportunity in the first recurrence group, with around 20% of total prescriptions coming from this setting, reflecting increased confidence among healthcare professionals [24][26] Question: Patient drop-off and new start outlook for KPL-387 - Management indicated that patients are staying on therapy for an average of 30 months, with compliance over 85%, suggesting a positive outlook for KPL-387 [32][34] Question: Expansion of sales force and marketing strategies - Management is exploring further expansion of the sales force and innovative marketing strategies, including digital marketing and AI targeting [39][42][46] Question: Efficacy expectations for KPL-387 - Management stated that the efficacy profile for KPL-387 will be data-driven, with a focus on optimizing performance through the trial design [68][70] Question: Emerging competition in the market - Management acknowledged the presence of potential oral competitors but emphasized Kynixa's leadership in understanding the disease mechanism and the importance of IL-1 inhibition [68][70]

ARCALYST Performance and Market - ARCALYST has generated over $1 billion in revenue since its launch[7] - Expected 2025 ARCALYST revenue is projected to be between $625 million and $640 million[7, 51] - ARCALYST has achieved approximately 15% penetration into the target population of recurrent pericarditis patients as of Q2 2025[7, 23, 29] - Approximately 80% of ARCALYST prescriptions are for patients with ≥3rd recurrence[23] - Approximately 20% of ARCALYST prescriptions are for patients in their 1st recurrence[23] - Payer approval for ARCALYST exceeds 90% of completed cases[28] - Approximately 45% of patients restarted ARCALYST therapy following initial discontinuation within ~8 weeks[37, 40] - The average total duration of ARCALYST therapy is approximately 30 months[28, 40] Financial Position - Kiniksa reported Q2 2025 cash reserves of approximately $308 million[8] - Kiniksa's operating plan is expected to remain cash flow positive on an annual basis[7, 78] - ARCALYST net sales for Q2 2025 were $156.8 million, compared to $103.4 million in Q2 2024[77] KPL-387 Development - A Phase 2/3 trial for KPL-387 in recurrent pericarditis has been initiated, with Phase 2 dose-focusing data expected in the second half of 2026[8]

[Financial & Operational Highlights](index=1&type=section&id=Financial%20%26%20Operational%20Highlights) Kiniksa reported strong Q2 2025 results, driven by ARCALYST revenue growth, raised full-year guidance, and initiated a pivotal clinical trial ARCALYST Net Product Revenue | Metric | Q2 2025 (USD) | YoY Growth | | :--- | :--- | :--- | | ARCALYST Net Product Revenue | $156.8 million | 52% | ARCALYST Net Product Revenue Guidance | Guidance | Previous (USD) | Updated (USD) | | :--- | :--- | :--- | | 2025 ARCALYST Net Product Revenue | $590 - $605 million | $625 - $640 million | - Initiated the pivotal **Phase 2/3 clinical trial** of KPL-387 for recurrent pericarditis, with Phase 2 data anticipated in the second half of 2026[1](index=1&type=chunk)[3](index=3&type=chunk) - The cash balance increased by **$39.4 million** during the quarter, reaching **$307.8 million** as of June 30, 2025[1](index=1&type=chunk)[9](index=9&type=chunk) [Portfolio Execution](index=1&type=section&id=Portfolio%20Execution) Portfolio execution is driven by strong ARCALYST commercial performance and active advancement of KPL-387 and KPL-1161 in the clinical pipeline [ARCALYST (rilonacept)](index=1&type=section&id=ARCALYST%20%28rilonacept%29) ARCALYST demonstrates strong market penetration and sustained therapy duration in recurrent pericarditis patients - Since its launch, over **3,475 prescribers** have written ARCALYST prescriptions for recurrent pericarditis[4](index=4&type=chunk) - The average total duration of ARCALYST therapy for recurrent pericarditis reached approximately **30 months** by the end of Q2 2025[4](index=4&type=chunk) - As of Q2 2025 end, approximately **15%** of the target 14,000 patients with multiple recurrences were actively receiving ARCALYST treatment[4](index=4&type=chunk) [KPL-387](index=2&type=section&id=KPL-387) KPL-387 is actively recruiting for its Phase 2/3 trial, with data expected in late 2026 and potential market entry by 2028/2029 - Patient recruitment is underway for the dose-focusing portion of the **Phase 2/3 clinical trial** in recurrent pericarditis[5](index=5&type=chunk) - Data from the Phase 2 portion of the trial is expected in the **second half of 2026**, with potential market entry projected for the **2028/2029 timeframe**[3](index=3&type=chunk)[5](index=5&type=chunk) [KPL-1161](index=2&type=section&id=KPL-1161) KPL-1161 is undergoing IND-enabling development, targeting a convenient quarterly subcutaneous dosing profile - The company is conducting Investigational New Drug (IND)-enabling development activities for KPL-1161[6](index=6&type=chunk) - KPL-1161 is being developed with a target profile of **quarterly subcutaneous (SC) dosing**[6](index=6&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Performance) Kiniksa achieved significant revenue growth and transitioned to profitability in Q2 2025, maintaining a strong balance sheet with no debt [Financial Results (Q2 2025)](index=2&type=section&id=Financial%20Results%20%28Q2%202025%29) Q2 2025 financial results show significant revenue growth and a shift to net income, driven by ARCALYST sales Q2 2025 Financial Metrics | Financial Metric | Q2 2025 (USD) | Q2 2024 (USD) | | :--- | :--- | :--- | | Total Revenue | $156.8 million | $108.6 million | | Total Operating Expenses | $136.6 million | $108.7 million | | Net Income (Loss) | $17.8 million | ($3.9 million) | - The increase in total operating expenses was primarily driven by a rise in collaboration expenses related to ARCALYST's profitability, which grew to **$52.4 million** from **$30.0 million** year-over-year[9](index=9&type=chunk) [Financial Position (as of June 30, 2025)](index=2&type=section&id=Financial%20Position%20%28as%20of%20June%2030%2C%202025%29) The company's financial position as of June 30, 2025, reflects a strong cash balance and no outstanding debt Selected Balance Sheet Data | Balance Sheet Item | June 30, 2025 (USD) | December 31, 2024 (USD) | | :--- | :--- | :--- | | Cash, cash equivalents, and short-term investments | $307.8 million | $243.6 million | | Total Assets | $661.2 million | $580.6 million | | Total Shareholders' Equity | $495.0 million | $438.4 million | - As of June 30, 2025, Kiniksa had **no debt**[9](index=9&type=chunk) [Financial Guidance](index=2&type=section&id=Financial%20Guidance) Kiniksa raised its full-year 2025 ARCALYST revenue guidance and expects to remain cash flow positive annually - Raised 2025 ARCALYST net product revenue guidance to between **$625 million and $640 million**, up from the prior range of $590 million to $605 million[3](index=3&type=chunk)[9](index=9&type=chunk) - The company expects its current operating plan to remain **cash flow positive** on an annual basis[9](index=9&type=chunk) [Appendix: Financial Statements](index=6&type=section&id=Appendix%3A%20Financial%20Statements) This appendix provides unaudited consolidated statements of operations and selected balance sheet data for specified periods [Consolidated Statements of Operations](index=6&type=section&id=Consolidated%20Statements%20of%20Operations) This section presents the unaudited consolidated statements of operations for the three months ended June 30, 2025 and 2024 Consolidated Statements of Operations (Thousands USD) | Metric | Three Months Ended June 30, 2025 (Thousands USD) | Three Months Ended June 30, 2024 (Thousands USD) | | :--- | :--- | :--- | | **Total revenue** | **$156,797** | **$108,631** | | Product revenue, net | $156,797 | $103,394 | | **Total operating expenses** | **$136,637** | **$108,748** | | Cost of goods sold | $18,603 | $12,322 | | Collaboration expenses | $52,418 | $30,014 | | Research and development | $18,753 | $24,017 | | Selling, general and administrative | $46,863 | $42,395 | | **Income (loss) from operations** | **$20,160** | **($117)** | | **Net income (loss)** | **$17,832** | **($3,908)** | | **Net income (loss) per share—diluted** | **$0.23** | **($0.06)** | [Selected Consolidated Balance Sheet Data](index=7&type=section&id=Selected%20Consolidated%20Balance%20Sheet%20Data) This section provides selected unaudited consolidated balance sheet data as of June 30, 2025, and December 31, 2024 Selected Consolidated Balance Sheet Data (Thousands USD) | Balance Sheet Item | As of June 30, 2025 (Thousands USD) | As of December 31, 2024 (Thousands USD) | | :--- | :--- | :--- | | Cash, cash equivalents, and short-term investments | $307,782 | $243,627 | | Working capital | $302,484 | $231,178 | | Total assets | $661,150 | $580,553 | | Total shareholders' equity | $495,007 | $438,436 |

Core Insights - Kiniksa Pharmaceuticals reported a strong commercial performance in Q2 2025, with ARCALYST net product revenue reaching $156.8 million, reflecting a 52% year-over-year growth [1][2][8] - The company has raised its 2025 ARCALYST net sales guidance to between $625 million and $640 million, up from a previous range of $590 million to $605 million [2][13] - Kiniksa is advancing its clinical pipeline, with the initiation of the Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, expecting data in the second half of 2026 [4][15] Financial Performance - Total revenue for Q2 2025 was $156.8 million, compared to $108.6 million in Q2 2024 [8][22] - The net income for Q2 2025 was $17.8 million, a significant improvement from a net loss of $3.9 million in Q2 2024 [13][22] - Operating expenses for Q2 2025 totaled $136.6 million, up from $108.7 million in Q2 2024, with collaboration expenses increasing due to ARCALYST profitability [8][22] Product and Pipeline Updates - ARCALYST has been prescribed by over 3,475 prescribers for recurrent pericarditis, with an average treatment duration of approximately 30 months [7] - As of Q2 2025, about 15% of the target 14,000 multiple-recurrence patients are actively receiving ARCALYST treatment [7] - KPL-387 is in the dose-focusing portion of its Phase 2/3 trial, with plans for a pivotal trial to follow [4][15] Cash Position - Kiniksa's cash balance increased by $39.4 million in Q2 2025, reaching $307.8 million, with no debt reported [1][13][23] - The company expects to maintain a cash flow positive operating plan on an annual basis [13]

Core Viewpoint - Kiniksa Pharmaceuticals International, plc will host a conference call on July 29, 2025, to discuss its second quarter 2025 financial results and recent portfolio execution [1]. Group 1: Conference Call Details - The conference call will take place at 8:30 a.m. Eastern Time [1]. - A live webcast will be available on the company's website, and participants can register for telephone access [2]. - A replay of the event will be accessible on Kiniksa's website approximately 48 hours after the call [2]. Group 2: Company Overview - Kiniksa is a biopharmaceutical company focused on developing therapies for debilitating diseases, particularly in cardiovascular indications [3]. - The company aims to discover, acquire, develop, and commercialize novel therapies for diseases with unmet needs [3]. - Kiniksa's portfolio is based on strong biological rationale or validated mechanisms, offering potential for differentiation in the market [3].

ARCALYST Performance and Market - Kiniksa expects ARCALYST net product revenue of $220 million to $230 million in 2023, representing approximately 84% growth at the midpoint[13,51] - ARCALYST has achieved only about 5% penetration of the target recurrent pericarditis population as of the end of 2022[13] - Approximately 14,000 recurrent pericarditis patients in the U S suffer from persistent underlying disease[28] - The addressable U S opportunity for ARCALYST is estimated to be approximately 14,000 patients, with about 7,000 new patients entering the target pool annually[33,36] - In Q2 2023, ARCALYST product revenue reached $54.5 million, representing approximately 100% year-over-year growth[38] Financial Position and Licensing Agreements - Kiniksa's cash position was $185 million as of Q2 2023[13,21] - The company's cash runway extends into at least 2027, supported by a profitable ARCALYST collaboration and revenue from out-licensing agreements[13,21] - Kiniksa received a $22 million upfront payment from Huadong Medicine and is eligible for up to approximately $640 million in milestones and royalties[24] - Kiniksa has received $100 million in upfront and near-term payments from the Genentech transaction, and is eligible for up to approximately $600 million in milestones[24] KPL-404 Development - KPL-404, a potentially best-in-class asset, is currently in a Phase 2 study for rheumatoid arthritis[14,18] - The Phase 2 trial for KPL-404 in rheumatoid arthritis is a multiple-ascending-dose study evaluating PK and safety, transitioning into a parallel dose efficacy portion[72]